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Simple Summary: Soft tissue sarcomas (STS) are an uncommon and heterogeneous group of tumors,
with scarce options for treatment in advanced cases. There is no consensus regarding which is
the best treatment sequence for these patients. Although trabectedin is an approved drug for STS
treatment, after progression to anthracyclines, the clinical profile of the patients that most benefit
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from this drug it is not defined. We have retrospectively analyzed a sample of 357 nonselected
sarcoma patients from real-world experience, treated homogeneously with trabectedin, confirming
and validating results from previous clinical trials and other retrospective studies. After analyzing
clinical prognostic factors, we selected those which predicted a better growth modulation index
(GMI > 1.33), and we defined the GEISTRA score, an easy to obtain and reproducible clinical tool,
that can help us to optimize the use of trabectedin in advanced sarcoma patients.
Abstract: The aim of this study was to identify an easily reliable prognostic score that selects the
subset of advanced soft tissue sarcoma (ASTS) patients with a higher benefit with trabectedin in
terms of time to progression and overall survival. A retrospective series of 357 patients with ASTS
treated with trabectedin as second- or further-line in 19 centers across Spain was analyzed. First,
it was confirmed that patients with high growth modulation index (GMI > 1.33) were associated
with the better clinical outcome. Univariate and multivariate analyses were performed to identify
factors associated with a GMI > 1.33. Thus, GEISTRA score was based on metastasis free-interval
(MFI ≤ 9.7 months), Karnofsky < 80%, Non L-sarcomas and better response in the previous systemic
line. The median GMI was 0.82 (0–69), with 198 patients (55%) with a GMI < 1, 41 (11.5%) with a
GMI 1–1.33 and 118 (33.1%) with a GMI > 1.33. The lowest GEISTRA score showed a median of
time-to-progression (TTP) and overall survival (OS) of 5.7 and 19.5 months, respectively, whereas it
was 1.8 and 3.1 months for TTP and OS, respectively, for the GEISTRA 4 score. This prognostic tool
can contribute to better selecting candidates for trabectedin treatment in ASTS.
Keywords: trabectedin; sarcoma; growth modulation index; prognostic score; L-sarcoma; GEISTRA
1. Introduction
Soft tissue sarcomas (STS) are an uncommon and heterogeneous group of 64 locally
aggressive and/or malignant sarcoma subtypes according to the last WHO classification [1].
The number of STS histological subtypes has an increasing tendency, since new advances in
pathology and molecular diagnosis have diversified and created new sarcoma entities [1].
In patients with unresectable and/or metastatic disease not amenable to curative surgery,
the standard front-line treatment involves a palliative chemotherapy regimen with anthra-
cyclines. Although there is some evidence that addition of ifosfamide to anthracyclines can
achieve higher clinical benefits, no clear impact of such a combination was seen on overall
survival (OS) [2,3] Beyond first-line treatment, several drugs and combinations have been
widely introduced in daily clinical practice with different levels of activity and linked
with specific sarcoma subtypes [4]. Nevertheless, there is no consensus regarding which
is the best treatment sequence for patients with recurrent disease and different sarcoma
histotypes to obtain optimal results.
Trabectedin (Yondelis®, PharmaMar, S.A., Madrid, Spain) I s a semisynthetic drug
originally isolated from the Caribbean sea squirt Ecteinascidia turbinata. Trabectedin has a
pleiotropic mechanism of action affecting key cell biology processes in tumor cells as well
as in the tumor microenvironment with selective anti-inflammatory, immunomodulatory
and antiangiogenic properties [5–8]. All these mechanisms contribute to a characteristic
late response to trabectedin with a prolonged stabilization of tumor growth and dormancy
of metastases. Trabectedin was the first marine-derived antineoplastic drug approved
in 2007 in the European Union, and presently in about 80 countries across the world,
for the treatment of patients with advanced STS (ASTS) who progressed after failure of
anthracyclines and ifosfamide, or for those patients who are unsuitable to receive these
agents [9]. In 2015, trabectedin was also approved in the U.S. for patients with advanced
liposarcoma or leiomyosarcoma (commonly referred as L-sarcomas) based on the results of
a pivotal, randomized, phase III study that evaluated the efficacy and safety of trabectedin
as compared with dacarbazine, an active comparator used in the treatment of patients with
ASTS [10].
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Regarding the assessment of clinical benefit, the selection of clinically meaningful
scientific objectives and standardized study endpoints for recurrent disease is critical.
Nowadays, tumor growth delay seems to be a more informative objective than mere
tumor shrinkage. Therefore, time to event outcomes such as time to progression (TTP)
and progression-free survival (PFS) are considered as the preferred primary endpoints in
sarcoma trials [11]. In 1998, Von Hoff described an approach based on the use of intrapatient
comparison of successive TTP intervals where each couple tumor/patient acts as its own
control [12]. He defined the growth modulation index (GMI) as the ratio of the TTP with a
determined line of treatment (TTPn) divided by the TTP from the previous line of treatment
(TTPn-1). Since the successive TTPs tend to be shorter in subsequent treatment lines, it has
been suggested that GMI > 1.33 is the threshold that defines a drug as an agent of excellent
efficacy [13,14]. Thus far, this approach was used to evaluate the efficacy of trabectedin
in ASTS in two retrospective and one prospective study, confirming that GMI is a useful
exploratory efficacy endpoint and a good surrogate marker of drug activity, which also
considers the heterogeneity of each STS [13–15].
Based on the results of a preliminary analysis of data from 198 patients with ASTS
treated with trabectedin (training cohort), we previously defined a new GEISTRA score,
identifying L-sarcomas, metastatic-free interval (MFI) from initial diagnosis and Karnofsky
performance status (KS) as independently associated prognostic variables associated with
high GMI of >1.33 [16]. In this retrospective study, we have further analyzed data from 191
other patients considered as the validation cohort (total population: n = 357), with the aim
of validating the GEISTRA score and additionally characterizing a clinical profile of the
patients that may benefit most from trabectedin.
2. Materials and Methods
2.1. Database and Objectives
We carried out a retrospective study of the Spanish Group of Sarcoma Research (GEIS)
registry database with real-life patients’ data treated with trabectedin between January
2007 and June 2016. This trial was implemented in 18 representative GEIS centers with
the aim to have a good geographical representation of patients across Spain. The primary
objective of the study was to identify which group of patients with ASTS benefits most from
trabectedin given as a second- or later-line chemotherapy by evaluating the concordance
among the GMI > 1.33, response and survival outcomes, and the clinical characteristics
of patients. Secondary endpoint was to assess the efficacy of trabectedin according to
histological sarcoma subtype.
All study procedures were conducted in accordance with the ethical standards as
laid down in the 1964 Declaration of Helsinki and its later amendments, guidelines for
Good Clinical Practice and were approved by the institutional review boards of each
participating center. All reasonable efforts to obtain signed informed consent forms from
all study participants to retrieve their data and tumor samples were done before study
registration. All participant centers had to obtain the approval of ethics committees before
registration.
2.2. Patients and Treatments
All eligible patients had to be on treatment with trabectedin and have received a
minimum of one cycle of trabectedin as second- or later-line treatment before their inclusion
in the study. Eligible patients were adults (>18 years old) with histologically proven and
measurable ASTS who received an anthracycline-based treatment as first-line treatment,
and with data available to calculate survival outcomes. Patients who had received an
anthracycline as neo- and/or adjuvant treatment, and subsequently received trabectedin
as first advanced chemotherapy for recurrent/metastatic disease, were not included in
the analysis. Exclusion criteria included patients with contraindications to the use of
trabectedin as defined in the marketing authorization, patients with gastrointestinal stromal
tumor or bone sarcoma, and pregnant and breastfeeding women.
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Trabectedin was administered in accordance with the marketing authorization at the
recommended dose of 1.5 mg/m2 body surface area (BSA), administered as an intravenous
infusion over 24 h with a 3-week interval between cycles. Pretreatment with corticos-
teroids (e.g., dexamethasone 20 mg intravenously 30 min before trabectedin) was usually
prescribed for all patients receiving trabectedin.
2.3. GEISTRA Score Design
To develop the new score, the series was split into training and validation cohorts. The
training set was the original one which the model was stemmed from l [16]. The optimal
cutoff of the quantitative variable metastatic-free interval (MFI) was calculated through
Receiver Operating Curves (ROC). All the remaining patients included in the registry after
those included in the training set, were used as validation set.
The GMI was calculated as defined by Von Hoff [12] and was expressed as a ratio
of intrapatient successive TTPs: GMI = TTP under trabectedin/TTP for treatment prior
to trabectedin. TTPs were supplied by investigator centers, and there was no central
review. The TTP for treatment prior to trabectedin was calculated from the start date
of prior chemotherapy treatment to the date of progressive disease. To build a new
GEISTRA score in the training cohort, first we analyzed which independently associated
prognostic variables could predict a GMI > 1.33, indicating the highest clinical benefit from
the treatment with trabectedin. Subsequently, we assigned one point for each adversely
affected variable to produce the final rate of GEISTRA score, ranging from 0–4 points.
2.4. Statistical Methods
Variables following binomial distributions are expressed as frequencies and percent-
ages, whereas categorical variables are expressed as absolute and relative frequencies or
continuous variables as the median, range (minimum–maximum). Comparisons between
qualitative variables were done using the Fisher Exact Test or Chi-square. Comparisons be-
tween quantitative and qualitative variables were performed through nonparametric tests
(U of Mann–Whitney or Kruskal–Wallis tests). Multivariate analysis of the relationship be-
tween qualitative and binary variables was made with binary logistic regression to identify
and characterize the subgroup of patients with GMI > 1.33 (i.e., possible prognostic factors).
The objective response rate (ORR) of trabectedin was evaluated according to Response
Evaluation Criteria in Solid Tumors (RECIST) v.1.1 [17]. Moreover, the disease control rate
(DCR) was defined as the percentage of patients with a complete response (CR) or partial
response (PR) and/or stable disease (SD). Time-to-event endpoints and their fixed-time
estimations were estimated according to the Kaplan–Meier method and were compared
using the log-rank test. The TTP and OS analyses were defined as the time interval from
the date of diagnosis, metastasis or first administration of trabectedin to the earliest date
of disease progression or disease-related death as reported by the investigator for TTP,
whereas OS was defined as the time between the start of trabectedin and patient death from
any cause. Multivariate survival analysis with the variables that proved to be significant in
univariate analysis was performed according to the Cox proportional hazard regression
model. All p-values reported were two-sided, and the significance level selected was 0.05.
3. Results
3.1. Characteristics of Patients and Treatments
We collected data from 387 patients with ASTS enrolled by 19 GEIS centers across
Spain. Of those, 30 patients were considered as noneligible for analysis as they underwent
surgery between the prior chemotherapy and trabectedin and, thus, their GMIs could not
be properly calculated. Therefore, data from 357 patients were included in the analysis set.
Table 1 shows the whole series as well as training and validation cohorts. At diagnosis
patients had a median age of 50 years (range: 14–79 years), slightly more than half were
women (52.7%), and most had nonmetastatic disease (77.3%). L-sarcomas (54.1%) were the
most prevalent histological types of sarcomas (leiomyosarcoma 31.7%; liposarcoma 22.4%).
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Table 1. Patients’ characteristics.




n = 166 p
Age (Years) Median (range): 50 (14–79) 50 (14–78) 51 (14–79) 0.094
Sex
Men 169 (47.3) 98 (51.3) 70 (42.2)
0.11
Women 188 (52.7) 93 (48.7) 95 (57.6)
Histology
L-sarcoma 193 (54.1) 96 (50.3) 97 (58.4) 0.14
Leiomyosarcoma 113 (31.7)) 57 (29.8) 56 (33.7) 0.49
Liposarcoma 80 (22.4) 39 (20.4) 41 (24.7) 0.37
Non-L-sarcoma 164 (45.9) 95 (49.7) 69 (41.6) 0.14
UPS 37 (10.4) 27 (14.1) 10 (6) 0.014
Other 127 (35.6) 68 (35.6) 59 (35.5) 1
TR-sarcoma 92 (25.7) 50 (26.2) 42 (25.3)
0.904
Non-TR-sarcoma 265 (74.2) 141 (73.8) 124 (74.7)
FNCLCC tumor grade a
1 44 (12.3) 23 (12) 21 (12.7)
0.47
2 89 (24.9) 43 (22.5) 46 (27.7)
3 187 (52.4) 105 (55) 82 (49.4)
Missing 37 (10.4) 20 (10.5) 17 (10.2)
Prior chemotherapy lines for
advanced disease
0–1 154 (43.1) 75 (39.3) 79 (47.6)
0.242 135 (37.8) 79 (41.3) 56 (33.7)




treatment 133 (37.3) 60 (31.4) 73 (44)
0.016
First-line for
advanced disease 224 (62.7) 131 (68.6) 93 (56)
Stage at initial diagnosis
Nonmetastatic 276 (77.3) 146 (76.4) 130 (78.3)
0.52Metastatic disease 78 (21.8) 45 (23.6) 33 (19.9)
Missing 3 (0.8) 0 (0) 3 (1.8)
Metastasis-free interval
(months) Median (range) 10.4 (0–177.2) 10.1 (0–174.5) 10.4 (0–177.2) 0.32
Karnofsky performance status
0–80 199 (55.7) 142 (55.3) 57 (58.8)
0.39>80 153 (42.8) 115 (44.7) 38 (39.2)
Missing 5 (1.4) 3 (1.2) 2 (2.1)
a Tumor specimens were classified according to the French Federation of Cancer Centers Sarcoma Group (FNCLCC) criteria. L-sarcoma,
leiomyosarcoma and liposarcoma; TR-sarcoma, translocation-related sarcoma; UPS, undifferentiated pleomorphic sarcoma.
All patients were pretreated with an anthracycline-based chemotherapy regimen,
133 (37.3%) as first-line treatment for metastatic STS, whereas the rest were treated in the
adjuvant setting. Additionally, 115 patients (32.2%) were also pretreated with gemcitabine-
based chemotherapy. Patients received a median of 4 trabectedin cycles per patient (range:
1–42). Overall, 154 patients (43.1%) received trabectedin as second-line chemotherapy, 15 of
whom immediately after anthracycline-based treatment. The rest of the patients received
trabectedin either as third- (n = 135, 37.8%) or fourth-line (n = 68, 19%) chemotherapy.
3.2. Response to Treatment and Survival Analysis
A total of 325 patients (91.0%) were evaluable for efficacy according to RECIST, given
that 27 patients were treated with ≤2 trabectedin cycles and global deterioration of the
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health status requiring discontinuation of the treatment before any assessment in nine pa-
tients. Five patients (1.5%) had a complete response (CR) and 36 patients (11.1%) achieved
a partial response (PR), reaching an ORR of 12.6%. CR cases were achieved in patients with
the following histotypes: 3 liposarcomas (2 myxoid, 1 dedifferentiated), and 2 synovial
sarcoma patients.
Additionally, 115 patients (35.4%) had stable disease as best response for a DCR of
48.0% (n = 156). All other evaluable patients (n = 169, 52.0%) showed progression as the
best response.
Considering the whole series, after a median follow-up of 75.1 months (range: 8.4–286.1)
from initial diagnosis, treatment with trabectedin resulted in a median OS of 12.0 months
(95% CI: 10–13.9) in the whole population and 17.9 months (95% CI: 14.3–21.5) in pa-
tients with L-sarcomas. Median OS from initial diagnosis and metastatic disease was 42.9
months (95% CI: 37.7–48) and 27.7 months (95% CI: 24.5–30.9), respectively. Patients with
L-sarcomas compared to patients with non-L-sarcomas obtained larger median OS from
initial diagnosis (55.8 months (95% CI: 46.6–65.1) vs. 34.8 months (95% CI: 28.6–41)) and
from metastatic disease diagnosis (33.9 months (95% CI: 29.1–38.6) vs. 21.4 months (95%
CI: 18.2–24.6)).
The median TTP for the immediately prior chemotherapy line was 2.6 months (95%
CI: 2.4–2.8), whereas median TTP for trabectedin was 3.5 months (95% CI: 2.8–4.0). Median
TTP from trabectedin significantly differed (p < 0.001) in patients with L-sarcomas as
compared with patients with non-L-sarcomas (5.1 months [95% CI: 3.8–6.4] vs. 2.8 months
[95% CI: 2.3–3.3]). Exploratory univariate and multivariate analyses identified metastasis-
free interval (MFI) <10 months, Karnofsky performance status <80%, non-L-sarcoma and
grade 3 sarcoma as per the French Federation of Cancer Centers Sarcoma Group (FNCLCC)
criteria as independent prognostic factors associated with both worse TTP and OS (Table 2).
Table 2. Univariate and multivariate analysis of prognostic factors for worse TTP and OS.
Univariate Analysis HR (95% CI) Multivariate Analysis HR (95% CI)




0.001 0.002 <0.001 0.012.8 (2.3–3.2) 8 (5.7–10.2) 1.6 (1.2–2.0) 1.4 (1.1–1.9)




0.047 0.022 0.67 0.513.5 (2.9–4) 11.7 (9.2–14.1) 0.9 (0.6–1.3) 1.1 (0.8–1.7)




0.16 0.0813.7 (2.7–4.6) 13.5 (10.1–16.9)




0.5 0.0983.7 (3.1–4.4) 10.2 (7.7–12.7)




<0.001 <0.001 <0.001 <0.0015.9 (4–7.7) 19.5 (16.8–22.2)
2.7 (2.3–3) 7.4 (5.4–9.4) 1.6 (1.2–2.1) 1.9 (1.5–2.5)




<0.001 <0.001 0.015 0.027
7.6 (5.4–9.8) 25.7 (13.8–37.6)
3.7 (2.2–5.2) 15.2 (10.9–19.4)




<0.001 <0.001 <0.001 <0.0015.1 (3.8–6.4) 17.9 (14.3–21.5)







<0.0012.2 (1.6–3) 3.7 (2.5–4.9)






0.2933.3 (2.7–3.8) 11.6 (9.3–13.8)
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Table 2. Cont.
Univariate Analysis HR (95% CI) Multivariate Analysis HR (95% CI)






3 (2.4–3.5) 10.6 (8–13.2)
4.6 (3–6.1) 17 (12–22)




0.15 13.8 (2.7–4.8) 13.1 (8.9–17.3)




0.091 0.833.4 (2.9–3.9) 12.2 (9.3–15.2)
3.8 (2.9–4.7) 12 (9.4–14.6)






3.8 (2.8–4.8) 12.2 (8.8–15.7)
3.8 (3.1–4.5) 13.1 (10.8–15.5)
3.3 (2.5–4) 9.2 (5.4–13.1)
a Tumor specimens were classified according to the French Federation of Cancer Centers Sarcoma Group (FNCLCC) criteria. b Drugs given
immediately prior to treatment with trabectedin. CI, confidence interval; CR, complete response; OS, overall survival; HR, hazard ratio; PD,
progressive disease; PR, partial response; PS, performance status; SD, stable disease; TR-sarcoma, translocation-related sarcoma; TTP, time
to progression.
3.3. GEISTRA Score
In the training cohort (n = 191), the median GMI (mGMI) was 0.91 (0–69). Overall, 101
patients (52.9%) had a GMI < 1, 22 patients (11.5%) a GMI equal to 1–1.33 and 68 (35.6%)
had a GMI > 1.33. We found a statistically significant association between the GMI > 1.33
and median OS and TTP (p < 0.001; Table 3). There was also a high concordance rate
between the best objective response to trabectedin and the GMI > 1.33 (p < 0.001; Table 3).
Table 3. Relation between the GMI and other activity end-points in the training cohort.






7 (6.4%) 14 (20.5%)
21 (19.1%) 39 (57.4%)
82 (74.5%) 15 (22.1%)
Median OS from trabectedin (95% CI) 6.4 (4–8.9) 25.2 (14–36.4) <0.001
Median OS from initial diagnosis (95% CI) 34.8 (30.2–39.4) 64.6 (51.1–78.1) <0.001
Median OS from metastatic disease (95% CI) 23 (17.3–28.6) 32.7 (27.8–37.7) <0.001
Median TTP trabectedin (95% CI) 2.3 (2–2.6) 8.2 (6.2–10.1) <0.001
GMI, growth modulation index; OS, overall survival; TTP, time to progression.
Table 4 depicts the results of the univariate logistic analysis of clinical prognostic
factors related to GMI in the training cohort. Variables found to be significantly different in
the univariate analysis were included in multivariate analysis. Four variables were found
to be independently associated to GMI > 1.33: MFI > 5, Karnofsky performance status >80%,
L-sarcoma histology, and progression after the prior chemotherapy line. Those factors
were included in a multivariate analysis and also resulted to be significantly associated to
GMI > 1.33 (Table 4).
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Table 4. Univariate and multivariate analysis of variables in relation to growth modulation index (GMI) in the
training cohort.
Prognostic Factors Univariate Analysis Multivariate Analysis




0.003 0.0152 (46%) 13 (22%)




0.01336 (29%) 9 (13%)




164 (52%) 35 (51%)




0.3760 (49%) 38 (56%)




0.039 0.04473 (61%) 29 (43%)
47 (39%) 39 (57%) 2.14 (1.02–4.5)





13 (12%) 10 (16%)
30 (27%) 13 (21%)




0.023 0.03154 (44%) 42 (62%) 2.26 (1.08–4.74)






54 (44%) 42 (62%)
22 (18%) 5 (7%)











32 (26%) 5 (8%)
34 (28%) 11 (17%)




<0.001 <0.00166 (54%) 16 (25%)




0.2635 (28%) 25 (37%)




0.5454 (44%) 26 (38%)
69 (56%) 42 (62%)






41 (33%) 34 (50%)
52 (42%) 27 (40%)
30 (24%) 7 (10%)
a Tumor specimens were classified according to the French Federation of Cancer Centers Sarcoma Group (FNCLCC) criteria. CR, complete
response; GMI, growth modulation index; PD, progressive disease; PR, partial response; PS, performance status; SD, stable disease;
TR-sarcoma, translocation-related sarcoma; UPS, undifferentiated pleomorphic sarcoma.
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The GEISTRA score was defined taking into account these four variables, assigning
one point for each variable: MFI 0–5 months, Karnofsky performance status <80%, non-L-
sarcoma histology, and clinical benefit (i.e., CR/PR/SD) of previous line. Based on those
variables, we defined three prognostic staging groups: a GEISTRA group 0 for a total score
between 0–1 points and group 1 for a score of 2–4 points. Finally, we observed a statistically
significant correlation between the lower scores of the two-stage GEISTRA score and larger
median TTP and median OS (p < 0.001) following the treatment with trabectedin as shown
in Table 5 and Figure 1. We validated the score using the validation cohort as we can see in
Figure 1.







p < 0.001 
p < 0.001 
Figure 1. Cont.







Figure 1. Time to progression and overall survival curves according to GEISTRA score in the training (A,B) and validation 
(C,D) cohorts.  
4. Discussion 
This retrospective analysis of clinicopathological prognostic variables aimed to iden-
tify patients obtaining a higher benefit with trabectedin treatment as second or further 
line for progressing ASTS. With this in mind, a new GMI-based score, GEISTRA, which 
showed a strong correlation with clinical efficacy endpoints (ORR, TTP and OS) was de-
fined. We previously defined this score in a training cohort, and validated with an addi-
tional validation cohort [16]. Specifically, the independent worse prognostic variables 
comprising the GEISTRA score were MFI < 5 months, Karnofsky < 80%, Non L-sarcomas 
and obtaining clinical benefit rate in the previous systemic line. 
p = 0.017 
p = 0.004 
Figure 1. Time to progression and overall survival curves according to GEISTRA score in the training (A,B) and validation
(C,D) cohorts.
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Table 5. Correlation between GEISTRA score and time-to-event outcomes from trabectedin therapy in the training and
validation cohort.
Training Cohort Validation Cohort
























0.0041 2–4 2.5 (2–3) 7.4 (5.7–9.2) 3.1(2.3–3.9)
10.5
(5.3–15.7)
Whole series 3.4 (2.8–4) 11.2(8.9–13.5) 3.4 (2.8–4)
11.2
(8.9–13.5)
CI, confidence Interval; TTP: Time to Progression; OS: Overall Survival; mTTP: Median TTP; mOS: median OS.
4. Discussion
This retrospective analysis of clinicopathological prognostic variables aimed to identify
patients obtaining a higher benefit with trabectedin treatment as second or further line for
progressing ASTS. With this in mind, a new GMI-based score, GEISTRA, which showed
a strong correlation with clinical efficacy endpoints (ORR, TTP and OS) was defined.
We previously defined this score in a training cohort, and validated with an additional
validation cohort [16]. Specifically, the independent worse prognostic variables comprising
the GEISTRA score were MFI < 5 months, Karnofsky < 80%, Non L-sarcomas and obtaining
clinical benefit rate in the previous systemic line.
MFI was identified as a prognostic factor for first and second lines in advanced STS
by EORTC trials [18]. In fact, MFI was an independent prognostic variable for a better
progression free survival in ASTS patients treated with a second or further line [19]. A
longer MFI could reflect a more indolent tumor biological behavior that could be related
with a slower proliferation also in advanced disease. In line with that, the median time to
response for trabectedin ranges from 3.7 to 5.3 in prospective phase II trials [20,21], which
could indicate that indolent tumors are a favorable profile for trabectedin efficacy.
Despite the fact that trabectedin can be effective across a wider range of sarcoma
subtypes such as translocation-related sarcomas, undifferentiated pleomorphic sarcomas
or synovial sarcoma [22,23], the fact is that pivotal trials of trabectedin have been con-
ducted in L-sarcomas, precisely because a greater benefit of trabectedin is obtained in
this context [10]. Myxoid liposarcoma is a particularly sensitive subtype to trabectedin,
where a new mechanism of action was described for this drug through the displacement of
oncogenic transcription factor from the target promoter [24]. Even though other histologic
grouping could be performed, it was preferred to consider non-L vs. L-sarcomas as roughly
half of patients were distributed in each group.
Not surprisingly, performance status at the time of trabectedin initiation resulted in an
independent prognostic variable. Performance status has shown to be a robust prognostic
variable in ASTS [25]. In reality, the fact that response probability and the overall survival
are shortened with increasing systemic lines in ASTS [26] could be related to an impairment
of performance status.
More remarkable is the variable related to obtaining any response or stabilization
with the right previous line as a worse prognostic factor. This obviously has to do with
some selection bias inherent to targeting the population with GMI > 1.33. Nevertheless,
analyzing the median TTP in patients with progressive disease or the objective response
to the previous line, they were almost similar (9.9 vs. 16 months), so we do not consider
that its influence on GMI is so remarkable. On the other hand, what we consider clinically
relevant, and noteworthy to take into consideration, is the fact that progressive disease,
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as the best RECIST response in the previous systemic line, does not preclude trabectedin
efficacy.
Being the ORR below 10% for the registered drugs in second lines of ASTS, other
prognostic tools, such as GEISTRA, showing a good correlation to PFS and OS appear
appealing.
To the best of our knowledge, the combination of these clinical parameters, widely
and easily available in clinical practice, has not been previously studied in a large cohort of
treated ASTS patients.
In the present study trabectedin administration resulted in an ORR of 12.6%, DCR of
48.0%, and a median TTP and OS of 3.5 and 12.0 months, respectively. These figures are
similar to previously reported clinical trials with trabectedin in ASTS [9,10,15,23] as well
as to retrospective studies [27–30] (Supplementary Table S1). It is noteworthy that despite
our series containing 45.9% of non-L-sarcomas, clinical endpoints were similar to series
only focusing on L-sarcomas. Nevertheless, slightly better results than published have
been found in our series among L-sarcomas for both, median TTP and OS. Generally, there
are sparse data addressing prognostic or predictive scores in ASTS, as just a few studies
have previously described prognostic scores and typically among patients with localized
disease [31,32]. For instance, Penel et al. reported the statistically significant relationship
between a high GMI and favorable efficacy outcomes in patients treated with trabectedin
(i.e., ORR, TTP and OS) [14]. High GMI rates seen for trabectedin in the present study
(GMI 1–1.33: 11.5%; GMI > 1.33: 33.1%) favorably compare to Penel study [14] which
reported 7.5% and 29.0% of patients with a GMI of 1–1.33 and a GMI > 1.33, respectively.
Besides, Cousin reported a significant correlation between those with GMI > 1.33 and OS
in a retrospective multicenter study in patients with ASTS receiving an active second-line
after doxorubicin-based regimens [13]. It is noteworthy that the median GMI (mGMI) of
0.82 obtained in this study is in the range of other series treated with trabectedin, such as
those reported by Penel et al. (mGMI: 0.6) [14], Buonadonna et al. (mGMI:0.8) [15] Cousin
et al. (mGMI:0.75) [13] and Kobayashi et al. (mGMI:0.91) [30], despite the large proportion
of patients (45.9%) with non-L sarcomas. This indicates that a consistent benefit is reached
with trabectedin in a substantial number of patients in second line of ASTS. Considering
that median of PFS is decreasing as the number of lines in ASTS (and in general in all
tumors) increases due to more aggressive tumor phenotype and to the more fragile host, a
median GMI close to the unit indicates a very good option for a drug prescribed at least in
second line of ASPS.
In contrast to previous findings regarding a lower trabectedin efficacy in the context of
a higher number of previous lines [32], we did not find this factor of prognostic relevance.
However, it should be considered that those patients receiving trabectedin as a first line of
ASTS, as they had received anthracyclines and ifosfamide in a perioperative setting, have
not been included in our study.
Gemcitabine-based treatment is one of the most widely used second-line chemother-
apy schedules in ASTS. In our study, previous administration of gemcitabine-based treat-
ment apparently did not have any influence on trabectedin efficacy, as we found no
correlation between gemcitabine treatment and GMI, nor any significant prognostic value.
The fact of having selected variables related to patients with GMI > 1.33 can be helpful
to understand the utmost benefit profile of patients from trabectedin. However, a limitation
of our approach is that patients with GMI between 1 and 1.33 can also obtain substantial
benefit from trabectedin, and have not been included in our analysis. Apart from the
limited number of patients, the retrospective nature of this study makes impossible the
analysis of other important issues such as toxicity.
It could also be worthwhile to validate the prognostic role of emerging blood cell
rates as platelet/lymphoid or neuthophil/lymphoid cells in the context of advanced STS.
Likewise GEISTRA, these rates can be routinely used in a daily basis and could complement
our score [29].
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Few studies explored molecular and genetic biomarkers as potential predictors of
trabectedin efficacy [33]. In this sense, p53 and FAS expression predicted efficacy of
trabectedin and doxorubicin at first line of ASTS [34]. Other studies investigated the
nucleotide excision repair and homologous recombination DNA repair pathways, and
found a significant correlation between better response and low BRCA1 mRNA expression
and high ERCC1 or ERCC5 expression [35,36].
5. Conclusions
In conclusion, the GEISTRA score represents an easily applicable clinical tool that can
be useful and reliable to better predict which patients with ASTS are the best candidates
for the treatment with trabectedin in clinical practice.
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33. Blay, J.-Y.; Casali, P.G.; Nieto, A.; Tanović, A.; Le Cesne, A. Efficacy and Safety of Trabectedin as an Early Treatment for Advanced
or Metastatic Liposarcoma and Leiomyosarcoma. Futur. Oncol. 2014, 10, 59–68. [CrossRef] [PubMed]
34. Martin-Broto, J.; Pousa, A.L.; Peñas, R.D.L.; Del Muro, X.G.; Gutierrez, A.; Martinez-Trufero, J.; Cruz, J.; Alvarez, R.; Cubedo, R.;
Redondo, A.; et al. Randomized Phase II Study of Trabectedin and Doxorubicin Compared with Doxorubicin Alone as First-Line
Treatment in Patients With Advanced Soft Tissue Sarcomas: A Spanish Group for Research on Sarcoma Study. J. Clin. Oncol. 2016,
34, 2294–2302. [CrossRef] [PubMed]
35. Italiano, A.; Laurand, A.; Laroche, A.; Casali, P.; Sanfilippo, R.; Le Cesne, A.; Judson, I.; Blay, J.-Y.; Ray-Coquard, I.; Bui, B.; et al.
ERCC5/XPG, ERCC1, and BRCA1 Gene Status and Clinical Benefit of Trabectedin in Patients with Soft Tissue Sarcoma. Cancer
2011, 117, 3445–3456. [CrossRef]
36. Schöffski, P.; Taron, M.; Jimeno, J.; Grosso, F.; Sanfilipio, R.; Casali, P.; Le Cesne, A.; Jones, R.; Blay, J.-Y.; Poveda, A.; et al.
Predictive Impact of DNA Repair Functionality on Clinical Outcome of Advanced Sarcoma Patients Treated with Trabectedin:
A Retrospective Multicentric Study. Eur. J. Cancer 2011, 47, 1006–1012. [CrossRef] [PubMed]
